For a study, researchers sought to determine the effectiveness of RCTs on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). For RCTs (original publications) on CP/CPPS published between the creation of the database and 2021, they searched PubMed, Web of Science, and Embase. The modified Jadad scale and the Consolidated Standards of Reporting of Trials (CONSORT) statement were used to evaluate the RCT’s quality. There were a total of 77 RCTs included. The evaluation found that only 6 papers (7.79%) detailed allocation concealment methods, about 26 (33.77%) articles mentioned the “blind method,” and 26 (33.77%) papers gave descriptions of specific random procedures. The number of patients who withdrew from the RCTs was disclosed in 34 (44.16%) publications, and 67 (87.01%) studies included adverse events. The computation of sample size, registration of clinical trials, and details of pertinent research funding were, however, rarely disclosed in reports. Furthermore, 58 (75.32%) reports had Jadad scale scores of 3 points, while 19 (24.68%) reports had scores of 4 points. The quality of RCT reports on CP/CPPS still had to be substantially enhanced, and the RCT results should only be accepted and used sparingly. To standardize the design and execution of RCTs, increase their quality, and offer trustworthy data for the treatment of CP/CPPS, it was advised that investigators adhere to the CONSORT statement and the improved Jadad scale.

 

Source: bmcurol.biomedcentral.com/articles/10.1186/s12894-022-01078-5